Skip to main content
. Author manuscript; available in PMC: 2017 May 11.
Published in final edited form as: Pharmacol Biochem Behav. 2010 Apr 18;96(1):75–81. doi: 10.1016/j.pbb.2010.04.009

Table 3.

Effects of the D2 antagonist raclopride on measures of operant responding, as well as constants of the regression equation with responding entered as the DV. See text for specific analyses. Values represent means (±S.E.M.).

Dose Raclopride
Measure Vehicle 0.05 0.1 0.2 0.4 Regression Equation (DV = Responses)
Overall Responses 1140.1
(63.9)		 1258.0
(88.5)		 1035.0
(144.9)		 724.4
(176.5)* 		172.9
(156.4)** 		Slope Y- Intercept R2
Total Pause Time (s) 637.3
(82.8)		 485.9
(83.9)		 685.7
(144.7)		 936.1
(177.1)		 1579.0
(184.7)** 		−.95 †† 1687.3 .881
Average Pause Length (s) 16.9
(4.31)		 12.2
(3.88)		 16.4
(4.75)		 28.3
(9.30)		 883.9
(326.5)** 		−18.3 †† 1363.1 .506
Bin 1 (% all IRTs) 27.2
(2.75)		 24.9
(2.80)		 20.9
(1.94)		 17.6
(3.77)* 		3.27
(3.02)** 		34.8 †† 239.7 .573
Bin 2 (% all IRTs) 33.6
(2.29)		 34.75
(1.85)		 34.0
(1.39)		 25.5
(4.27)		 5.42
(3.62)** 		31.7 †† 25.5 .510
Pauses (% all IRTs) 4.18
(0.44)		 4.35
(0.71)		 7.03
(2.41)		 13.5
(4.24)		 51.0
(13.3)** 		−51.6 †† 1400.6 .524
*

p < .05,

**

p < .01 versus vehicle via planned comparisons.

††

Slope of regression equation is significantly different from zero, p < .01. Slope and Y-intercept for Pauses excludes sessions with >15%; those for Pause Length exclude values >60s.